Genovate Biotechnology Co Ltd (4130) — Capital Reinvestment Ratio
Genovate Biotechnology Co Ltd (4130) has a Capital Reinvestment Ratio of 0.48x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$16.93 Million) in capital expenditures (NT$8.19 Million). See net asset quality index of Genovate Biotechnology Co Ltd to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Genovate Biotechnology Co Ltd Capital Reinvestment Ratio (2015–2025)
This chart tracks Genovate Biotechnology Co Ltd's Capital Reinvestment Ratio across 10 annual periods. Check Genovate Biotechnology Co Ltd (4130) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Genovate Biotechnology Co Ltd (2015–2025)
Year-by-year Capital Reinvestment Ratio for Genovate Biotechnology Co Ltd from 2015 to 2025. For live market cap and broader valuation context, see 4130 market cap.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.40x | NT$43.79 Million | NT$61.42 Million | ▲ +146.4% |
| 2024 | 0.57x | NT$55.11 Million | NT$31.37 Million | ▲ +44.7% |
| 2023 | 0.39x | NT$84.78 Million | NT$33.34 Million | ▼ -97.5% |
| 2022 | 15.90x | NT$1.51 Million | NT$24.01 Million | ▲ +5026.6% |
| 2020 | 0.31x | NT$87.08 Million | NT$27.01 Million | ▼ -46.5% |
| 2019 | 0.58x | NT$44.43 Million | NT$25.76 Million | ▲ +3.4% |
| 2018 | 0.56x | NT$62.88 Million | NT$35.26 Million | ▼ -54.5% |
| 2017 | 1.23x | NT$31.27 Million | NT$38.53 Million | ▲ +112.8% |
| 2016 | 0.58x | NT$70.58 Million | NT$40.87 Million | ▼ -65.0% |
| 2015 | 1.65x | NT$32.53 Million | NT$53.75 Million | — |